… , non-hospitalized patients with at least one risk factor for severe Coronavirus disease 2019
(COVID-19). Treatment … Treatment was given to adult patients with mild to moderate COVID-…

… and molnupiravir (MPV)—were granted emergency use authorization by the Food and Drug
Administration for treatment … In a phase 2/3 double-blind randomized trial in adults who were …

… were treatment with a monoclonal antibody, convalescent plasma, or molnupiravir for the …
NMV-r with placebo in unvaccinated, nonhospitalized adults with mild–moderate COVID-19 at …

… with a substantially lower risk than treatment with molnupiravir (hazard ratio 0.54, 95% …
in preventing severe outcomes from SARS-CoV-2 infection in adult patients in England with …

… It is mentioned in the plan that the applicable population of molnupiravir is adult patients
with mild and moderate disease within 5 days of onset and high-risk factors for progression to …

… plus ritonavir (NMV-r) and molnupiravir (MOV) have demonstrated good efficacy in
reducing the risk of hospitalization and death in non-hospitalized adult patients with mild-to-moderate …

… -19 adult patients during … treatment with nirmatrelvir/ritonavir versus sotrovimab administered
by CMDUs in the main study, and treatment with nirmatrelvir/ritonavir versus molnupiravir in …

… interest in finding outpatient treatments that could prevent … effect sizes of available treatments
with respect to preventing … For molnupiravir, we included the published phase 3 trial [14]…

… treatment. Male partners of women with childbearing potential were required to ensure … for
the total treatment duration and at least three months after the end of Molnupiravir treatment. …

… at-risk, unvaccinated adults with COVID-19Citation 18 . … Non-hospitalized patients were
eligible for inclusion if they … receiving molnupiravir treatment (n = 409/470) received treatment …